These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
131 related articles for article (PubMed ID: 20694690)
1. Chemical microarrays: a new tool for discovery enzyme inhibitors. Liang S; Xu W; Horiuchi KY; Wang Y; Ma H Methods Mol Biol; 2009; 572():149-60. PubMed ID: 20694690 [TBL] [Abstract][Full Text] [Related]
2. Nanodroplet microarrays for high-throughput enzyme screening. Aw KL; Yao SQ; Uttamchandani M Methods Mol Biol; 2010; 669():79-93. PubMed ID: 20857359 [TBL] [Abstract][Full Text] [Related]
3. Chemical microarray: a new tool for drug screening and discovery. Ma H; Horiuchi KY Drug Discov Today; 2006 Jul; 11(13-14):661-8. PubMed ID: 16793536 [TBL] [Abstract][Full Text] [Related]
4. The use of diversity profiling to characterize chemical modulators of the histone deacetylases. Blackwell L; Norris J; Suto CM; Janzen WP Life Sci; 2008 May; 82(21-22):1050-8. PubMed ID: 18455194 [TBL] [Abstract][Full Text] [Related]
5. Opportunities and challenges for the development of covalent chemical immunomodulators. Backus KM; Cao J; Maddox SM Bioorg Med Chem; 2019 Aug; 27(15):3421-3439. PubMed ID: 31204229 [TBL] [Abstract][Full Text] [Related]
6. Next generation chemical proteomic tools for rapid enzyme profiling. Uttamchandani M; Lu CH; Yao SQ Acc Chem Res; 2009 Aug; 42(8):1183-92. PubMed ID: 19435360 [TBL] [Abstract][Full Text] [Related]
7. Nanoliter homogenous ultra-high throughput screening microarray for lead discoveries and IC50 profiling. Ma H; Horiuchi KY; Wang Y; Kucharewicz SA; Diamond SL Assay Drug Dev Technol; 2005 Apr; 3(2):177-87. PubMed ID: 15871692 [TBL] [Abstract][Full Text] [Related]
8. Nanodroplet profiling of enzymatic activities in a microarray. Uttamchandani M; Huang X; Chen GY; Yao SQ Bioorg Med Chem Lett; 2005 Apr; 15(8):2135-9. PubMed ID: 15808484 [TBL] [Abstract][Full Text] [Related]
9. Biochemical microarrays for studying chemical biology interaction: DiscoveryDot technology. Horiuchi KY; Wang Y; Ma H Chem Biol Drug Des; 2006 Jan; 67(1):87-8. PubMed ID: 16492155 [TBL] [Abstract][Full Text] [Related]
10. Microarray-based enzyme profiling: Recent advances and applications (Review). Uttamchandani M; Moochhala S Biointerphases; 2010 Sep; 5(3):FA24-31. PubMed ID: 21171709 [TBL] [Abstract][Full Text] [Related]
11. High throughput screening for biomaterials discovery. Algahtani MS; Scurr DJ; Hook AL; Anderson DG; Langer RS; Burley JC; Alexander MR; Davies MC J Control Release; 2014 Sep; 190():115-26. PubMed ID: 24993427 [TBL] [Abstract][Full Text] [Related]
12. Asymmetry of chemical similarity. Chen X; Brown FK ChemMedChem; 2007 Feb; 2(2):180-2. PubMed ID: 17177230 [No Abstract] [Full Text] [Related]
13. Developments in microarray technologies. Howbrook DN; van der Valk AM; O'Shaughnessy MC; Sarker DK; Baker SC; Lloyd AW Drug Discov Today; 2004 Dec; 9(24 Suppl):S1-9. PubMed ID: 23573653 [TBL] [Abstract][Full Text] [Related]
14. Screening for compounds that modulate epigenetic regulation of the transcriptome: an overview. Eglen RM; Reisine T J Biomol Screen; 2011 Dec; 16(10):1137-52. PubMed ID: 22002420 [TBL] [Abstract][Full Text] [Related]
15. Inhibition of phosphate-metabolizing enzymes by oxovanadium(V) complexes. Stankiewicz PJ; Tracey AS; Crans DC Met Ions Biol Syst; 1995; 31():287-324. PubMed ID: 8564811 [TBL] [Abstract][Full Text] [Related]
16. Recent developments in microarray-based enzyme assays: from functional annotation to substrate/inhibitor fingerprinting. Sun H; Chattopadhaya S; Wang J; Yao SQ Anal Bioanal Chem; 2006 Oct; 386(3):416-26. PubMed ID: 16791553 [TBL] [Abstract][Full Text] [Related]
17. Phosphatases: Their Roles in Cancer and Their Chemical Modulators. Fontanillo M; Köhn M Adv Exp Med Biol; 2016; 917():209-40. PubMed ID: 27236558 [TBL] [Abstract][Full Text] [Related]
18. Advancing the kinase field: new targets and second generation inhibitors. Laufer S; Bajorath J J Med Chem; 2015 Jan; 58(1):1. PubMed ID: 25490234 [No Abstract] [Full Text] [Related]
19. The druggability of intracellular nucleotide-degrading enzymes. Rampazzo C; Tozzi MG; Dumontet C; Jordheim LP Cancer Chemother Pharmacol; 2016 May; 77(5):883-93. PubMed ID: 26614508 [TBL] [Abstract][Full Text] [Related]
20. Case studies of minimizing nonspecific inhibitors in HTS campaigns that use assay-ready plates. Liu Y; Beresini MH; Johnson A; Mintzer R; Shah K; Clark K; Schmidt S; Lewis C; Liimatta M; Elliott LO; Gustafson A; Heise CE J Biomol Screen; 2012 Feb; 17(2):225-36. PubMed ID: 21940710 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]